Plain-English translation of NCT07387549 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help treat primary sclerosing cholangitis (PSC), a rare disease where the bile ducts in your liver become inflamed and scarred over time. About 350 adults will take part, and roughly half will receive the medication while the other half receive a placebo (a pill with no active ingredient). The study will track how well this treatment works and how safe it is.
PSC is a serious condition that can gradually damage the liver and lead to liver failure or transplant. Currently, there are limited treatment options available. This trial aims to see if this medication can slow down the disease and help people avoid these serious complications.
You likely qualify if…
You likely don't qualify if…
You would take one tablet by mouth every day — either the medication or a placebo. The study involves several years of participation, with regular visits for blood tests, liver imaging, and health assessments to track your liver disease and how you're doing. You'll also complete a follow-up visit about four weeks after the treatment ends. You can withdraw from the study at any time.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States